ROR1 and neoplasm: NBE-002, a next-generation ADC that targets ROR1, is the result of conjugation between huXBR1-402 humanized antibody with anthracycline PNU-159682 and binds to the immunoglobulin domain of human ROR1 and inhibit tumor cell growth [111, 129].